 Efavirenz/emtricitabine/tenofovir was approved for medical use in the United States in 2006, and in the European Union in 2007.It is on the World Health Organization's List of Essential Medicines, the safest and most effective medicines needed in a health system.The wholesale cost in the developing world is about US$10.71–14.19 per month as of 2014.